Hemispherx Biopharma Inc. Announces Updated Information about ME/CFS Expanded Access Program in the United States
OCALA, Fla., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, recently met with clinical patients at Hunter- …